Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 13, Issue 5, 2012, Pages 385-390

  Kim, Young Hak ^a   Sumiyoshi, Shinji ^b   Hashimoto, Seiji ^b   Masago, Katsuhiro ^a   Togashi, Yosuke ^a   Sakamori, Yuichi ^a   Okuda, Chiyuki ^a   Mio, Tadashi ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adenocarcinoma; IGF 1R; IGFBP3; Insulin like growth factor binding protein 3; Insulin like growth factor receptor 1; Non Small cell lung cancer; Squamous cell carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; NEDAPLATIN; PACLITAXEL; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; SMOKING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, IGF TYPE 1; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84865499918     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.11.009     Document Type: Article

References (16)

1. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
2. D.H. Johnson, L. Fehrenbacher, W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
3. M. Pollak Insulin and insulin-like growth factor signalling in neoplasia Nat Rev Cancer 8 2008 915 928
4. D.D. Karp, L.G. Paz-Ares, S. Novello Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer J Clin Oncol 27 2009 2516 2522
5. R. Dziadziuszko, D.R. Camidge, F.R. Hirsch The insulin-like growth factor pathway in lung cancer J Thorac Oncol 3 2008 815 818
6. Y.S. Chang, G. Kong, S. Sun Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer Clin Cancer Res 8 2002 3796 3802
7. R. Rami-Porta, J.J. Crowley, P. Goldstraw The revised TNM staging system for lung cancer Ann Thorac Cardiovasc Surg 15 2009 4 9
8. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
9. C.Y. Lee, J.H. Jeon, H.J. Kim Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis Korean J Intern Med 23 2008 116 120
10. R. Dziadziuszko, D.T. Merrick, S.E. Witta Insulin-like growth factor receptor 1 (IGF1R) protein expression, mRNA expression and gene copy number in operable non-small cell lung cancer (NSCLC) ASCO Meeting Abstracts 27 2009 7524
11. V. Ludovini, G. Bellezza, L. Pistola High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients Ann Oncol 20 2009 842 849
12. F. Cappuzzo, L. Toschi, G. Tallini Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib Ann Oncol 17 2006 1120 1127
13. J. Jassem, C.J. Langer, D.D. Karp Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) ASCO Meeting Abstracts 28 2010 7500
14. A. Gualberto, M. Dolled-Filhart, M. Gustavson Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition Clin Cancer Res 16 2010 4654 4665
15. Y.S. Chang, L. Wang, D. Liu Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer Clin Cancer Res 8 2002 3669 3675
16. H.Y. Lee, K.H. Chun, B. Liu Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer Cancer Res 62 2002 3530 3537